BCL2 and cancer: The activated PI3K/AKT/mTOR pathway can decrease the BCL-2 homology domain (BH3) mimetic effectiveness in cancer cells by upregulating anti-apoptotic BCL-2 family members, such as myeloid cell leukemia-1 (MCL-1) and B-cell lymphoma-extra large (BCL-XL) [79].